Envafolimab vs Sugemalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-L1 · full Non-Small Cell Lung Cancer pipeline

Envafolimab

Marketed by Suzhou Alphamab and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Weak signal

NCT05068427 · Phase 2 · completed

The study was an open-label, single-arm trial of 34 patients receiving chidamide plus envafolimab, with no randomized control group for comparison. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT05024214 (registry estimate)

Reported efficacy

objective response rate (ORR) (Response is assessed once every 8 weeks, assessed up to 24 weeks.): Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months (not_applicable)

Result source: NCT05068427

Sugemalimab · Cejemly

Marketed by CStone Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03728556 · Phase 3 · completed

In this randomized, quadruple-blind, placebo-controlled Phase 3 trial, 381 patients with stage III lung cancer who had completed chemoradiotherapy were randomized to sugemalimab or placebo. Sugemalimab significantly reduced the risk of progression or death compared with placebo (median progression-free survival 10.5 vs 6.2 months).

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: May 2027 · NCT07247227 (registry estimate)

Reported efficacy

Progress Free Survival (PFS) (from the date of randomization to the first date of recorded progression or all-cause death, whichever comes first, assessed up to 30 months.): Progression-free survival (BICR-assessed), GEMSTONE-301: median PFS 10.5 months (sugemalimab) vs 6.2 months (placebo); HR 0.65, 95% CI 0.50-0.84 (met)

Result source: NCT03728556

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnvafolimabSugemalimab
PFS, median—Trial running · NCT0612375410.5 vs 6.2a+4.3 vs placeboNCT03728556
OS, median—Trial running · NCT06123754—Not posted · NCT03728556
ORR—Trial running · NCT06123754—Not posted · NCT03728556
Duration of response, median—Trial running · NCT06123754—Not posted · NCT03728556

PFS, median

Envafolimab
—Trial running · NCT06123754
Sugemalimab
10.5 vs 6.2a+4.3 vs placeboNCT03728556

OS, median

Envafolimab
—Trial running · NCT06123754
Sugemalimab
—Not posted · NCT03728556

ORR

Envafolimab
—Trial running · NCT06123754
Sugemalimab
—Not posted · NCT03728556

Duration of response, median

Envafolimab
—Trial running · NCT06123754
Sugemalimab
—Not posted · NCT03728556
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Envafolimab
Primary endpoint ORR 6.7% (2/30); DCR 50% (15/30); median PFS 3.5 months NCT05068427 · Phase 2 · design grade: weak · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Sugemalimab

PFS 10.5 vs 6.2 placebo months
time to event · months
NCT03728556 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Envafolimab's landscape · Sugemalimab's landscape